Long-Term Disability Outcomes in Relapsing–Remitting Multiple Sclerosis Patients: Impact of Clinical and Demographic Factors on Disease Progression
<b<Background:</b< Multiple sclerosis (MS) is a prevalent chronic inflammatory and neurodegenerative disease of the central nervous system. The main evolving forms, relapsing–remitting MS (RRMS) and secondary progressive MS (SPMS), lack clear delineation. <b<Methods:</b< We conducted an observational study on 523 Caucasian RRMS patients receiving first-line disease-modifying therapies (DMTs), analyzing demographic, clinical, and geographical data. <b<Results:</b< RRMS patients experienced a statistically significant reduction in relapse rates post-DMT initiation. Significant differences in time to reach an Expanded Disability Status Score (EDSS) of 3.0 and 6.0 were observed based on demographics and onset topography. Kaplan–Meier analysis revealed that the onset with optic or supratentorial symptoms is linked to a longer time until EDSS = 3.0 is reached. Urban origin correlated with a prolonged time until EDSS = 3.0. Gender and environment showed no significant associations with the hazard of reaching an EDSS = 6.0. Cox regression analysis revealed no significant impact of relapses on the time to reach EDSS scores of 3.0 and 6.0 in our study cohort. <b<Conclusions:</b< Multivariate analysis identified several predictive factors for disability progression, including environment, age at onset, and disability level at DMT initiation..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Journal of Clinical Medicine - 13(2024), 6, p 1813 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Laura Barcutean [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
EDSS |
|---|
| doi: |
10.3390/jcm13061813 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ100484883 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ100484883 | ||
| 003 | DE-627 | ||
| 005 | 20240414095914.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240414s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm13061813 |2 doi | |
| 035 | |a (DE-627)DOAJ100484883 | ||
| 035 | |a (DE-599)DOAJ4db89408b0f144289c1ea399fbcd9bc9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Laura Barcutean |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-Term Disability Outcomes in Relapsing–Remitting Multiple Sclerosis Patients: Impact of Clinical and Demographic Factors on Disease Progression |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a <b<Background:</b< Multiple sclerosis (MS) is a prevalent chronic inflammatory and neurodegenerative disease of the central nervous system. The main evolving forms, relapsing–remitting MS (RRMS) and secondary progressive MS (SPMS), lack clear delineation. <b<Methods:</b< We conducted an observational study on 523 Caucasian RRMS patients receiving first-line disease-modifying therapies (DMTs), analyzing demographic, clinical, and geographical data. <b<Results:</b< RRMS patients experienced a statistically significant reduction in relapse rates post-DMT initiation. Significant differences in time to reach an Expanded Disability Status Score (EDSS) of 3.0 and 6.0 were observed based on demographics and onset topography. Kaplan–Meier analysis revealed that the onset with optic or supratentorial symptoms is linked to a longer time until EDSS = 3.0 is reached. Urban origin correlated with a prolonged time until EDSS = 3.0. Gender and environment showed no significant associations with the hazard of reaching an EDSS = 6.0. Cox regression analysis revealed no significant impact of relapses on the time to reach EDSS scores of 3.0 and 6.0 in our study cohort. <b<Conclusions:</b< Multivariate analysis identified several predictive factors for disability progression, including environment, age at onset, and disability level at DMT initiation. | ||
| 650 | 4 | |a multiple sclerosis | |
| 650 | 4 | |a progression | |
| 650 | 4 | |a relapsing–remitting | |
| 650 | 4 | |a secondary-progressive | |
| 650 | 4 | |a EDSS | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Smaranda Maier |e verfasserin |4 aut | |
| 700 | 0 | |a Zoltan Bajko |e verfasserin |4 aut | |
| 700 | 0 | |a Adina Stoian |e verfasserin |4 aut | |
| 700 | 0 | |a Oana Mosora |e verfasserin |4 aut | |
| 700 | 0 | |a Emanuela Sarmasan |e verfasserin |4 aut | |
| 700 | 0 | |a Ion-Bogdan Manescu |e verfasserin |4 aut | |
| 700 | 0 | |a Rodica Balasa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Journal of Clinical Medicine |d MDPI AG, 2013 |g 13(2024), 6, p 1813 |w (DE-627)DOAJ000006793 |x 20770383 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2024 |g number:6, p 1813 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/jcm13061813 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/4db89408b0f144289c1ea399fbcd9bc9 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/2077-0383/13/6/1813 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2077-0383 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2024 |e 6, p 1813 | ||